See more : Dignitana AB (publ) (DIGN.ST) Income Statement Analysis – Financial Results
Complete financial analysis of Protagonist Therapeutics, Inc. (PTGX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Protagonist Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Guangxi Guidong Electric Power Co., Ltd. (600310.SS) Income Statement Analysis – Financial Results
- Apogee 21 Holdings, Inc. (APHD) Income Statement Analysis – Financial Results
- Moneta Gold Inc. (ME.TO) Income Statement Analysis – Financial Results
- AFFIN Bank Berhad (5185.KL) Income Statement Analysis – Financial Results
- Monte Carlo Fashions Limited (MONTECARLO.BO) Income Statement Analysis – Financial Results
Protagonist Therapeutics, Inc. (PTGX)
About Protagonist Therapeutics, Inc.
Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with polycythemia vera and hereditary hemochromatosis, as well as for the treatment of other blood disorders; PN-943, an oral, alpha-4-beta-7 integrin- specific antagonist peptide that is in Phase II clinical trials for treating inflammatory bowel disease (IBD); and PN-235, an orally delivered interleukin-23 receptor specific antagonist for the treatment of IBD and non-IBD indications. The company has a license and collaboration agreement with Janssen Biotech, Inc. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 60.00M | 26.58M | 27.36M | 28.63M | 231.00K | 30.93M | 20.06M | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 1.03M | 2.78M | 0.00 | 0.00 | 0.00 | 0.00 | 317.00K | 247.00K | 0.00 |
| Gross Profit | 60.00M | 25.55M | 24.58M | 28.63M | 231.00K | 30.93M | 20.06M | -317.00K | -247.00K | 0.00 |
| Gross Profit Ratio | 100.00% | 96.12% | 89.86% | 100.00% | 100.00% | 100.00% | 100.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 120.16M | 126.22M | 126.01M | 74.51M | 65.00M | 59.50M | 46.18M | 25.71M | 11.83M | 7.46M |
| General & Administrative | 33.49M | 31.74M | 27.20M | 18.64M | 15.75M | 13.70M | 11.78M | 6.96M | 2.96M | 1.86M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 33.49M | 31.74M | 27.20M | 18.64M | 15.75M | 13.70M | 11.78M | 6.96M | 2.96M | 1.86M |
| Other Expenses | 0.00 | -80.00K | -149.00K | -46.00K | -1.00K | 0.00 | 0.00 | -34.00K | 0.00 | 0.00 |
| Operating Expenses | 153.65M | 157.95M | 153.20M | 93.14M | 80.75M | 73.19M | 57.96M | 32.67M | 14.79M | 9.32M |
| Cost & Expenses | 153.65M | 157.95M | 153.20M | 93.14M | 80.75M | 73.19M | 57.96M | 32.67M | 14.79M | 9.32M |
| Interest Income | 14.90M | 4.06M | 443.00K | 900.00K | 2.81M | 2.57M | 948.00K | 242.00K | 19.00K | 16.00K |
| Interest Expense | 0.00 | 0.00 | 0.00 | 598.00K | 169.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 3.31M | 1.03M | 2.78M | 789.00K | 703.00K | 527.00K | 406.00K | 317.00K | 247.00K | 258.00K |
| EBITDA | -90.34M | -131.37M | -123.07M | -63.66M | -78.31M | -39.20M | -36.55M | -32.35M | -14.55M | -9.06M |
| EBITDA Ratio | -150.57% | -494.24% | -458.94% | -222.38% | -33,640.26% | -136.68% | -188.89% | 0.00% | 0.00% | 0.00% |
| Operating Income | -93.65M | -131.37M | -125.85M | -64.52M | -80.52M | -42.27M | -37.90M | -32.67M | -14.79M | -9.32M |
| Operating Income Ratio | -156.09% | -494.24% | -460.01% | -225.36% | -34,857.58% | -136.68% | -188.89% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 14.70M | 3.98M | 294.00K | -329.00K | 2.64M | 2.55M | 940.00K | -4.51M | -64.00K | -1.75M |
| Income Before Tax | -78.96M | -127.39M | -125.55M | -64.85M | -77.88M | -39.72M | -36.96M | -37.18M | -14.86M | -11.07M |
| Income Before Tax Ratio | -131.59% | -479.26% | -458.94% | -226.51% | -33,713.42% | -128.45% | -184.20% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -3.98M | -2.92M | 1.31M | -691.00K | -799.00K | -406.00K | 4.16M | 64.00K | 1.75M |
| Net Income | -78.96M | -123.41M | -122.63M | -66.15M | -77.19M | -38.92M | -36.96M | -37.18M | -14.86M | -11.07M |
| Net Income Ratio | -131.59% | -464.29% | -448.25% | -231.07% | -33,414.29% | -125.87% | -184.20% | 0.00% | 0.00% | 0.00% |
| EPS | -1.39 | -2.52 | -2.65 | -1.92 | -2.98 | -1.74 | -2.09 | -5.72 | -2.52 | -1.88 |
| EPS Diluted | -1.39 | -2.52 | -2.65 | -1.92 | -2.98 | -1.74 | -2.09 | -5.72 | -2.52 | -1.88 |
| Weighted Avg Shares Out | 56.76M | 49.04M | 46.32M | 34.40M | 25.89M | 22.36M | 17.69M | 6.50M | 5.88M | 5.88M |
| Weighted Avg Shares Out (Dil) | 56.76M | 49.04M | 46.32M | 34.40M | 25.89M | 22.36M | 17.69M | 6.50M | 5.88M | 5.88M |
All You Need to Know About Protagonist Therapeutics (PTGX) Rating Upgrade to Buy
Protagonist Therapeutics (PTGX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Protagonist Therapeutics Provides Update on VERIFY Patient Enrollment and Timing of Top-line Data
On track to achieve 250 patient enrollment target in March 2024 Top-line data for 32-week primary endpoint expected in the first quarter of 2025 NEWARK, CA / ACCESSWIRE / March 26, 2024 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company")...
Wall Street Analysts Think Protagonist Therapeutics (PTGX) Could Surge 48.38%: Read This Before Placing a Bet
The consensus price target hints at a 48.4% upside potential for Protagonist Therapeutics (PTGX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an...
Protagonist Therapeutics Announces Closing of Worldwide Rusfertide License and Collaboration Agreement with Takeda
NEWARK, CA / ACCESSWIRE / March 18, 2024 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announces the closing of the worldwide collaboration and license agreement for rusfertide with Takeda, a leading values-based, R&D-driven biopharmaceutical company, disclosed on January...
4 Stocks to Buy for Attractive Earnings Acceleration
Invest in stocks such as Protagonist Therapeutics (PTGX), Evolus (EOLS), Western Digital (WDC), and Phunware (PHUN) as of now for superb earnings acceleration.
Protagonist Therapeutics to Participate in Upcoming Investor Conferences
NEWARK, CA / ACCESSWIRE / March 6, 2024 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced that they will participate in three upcoming investor conferences: Event: 2024 Jefferies Biotech on the Bay Summit Date: March 12-13, 2024Location: W...
4 Must-Buy Stocks for Remarkable Earnings Acceleration
Some of the notable companies to have witnessed solid earnings acceleration as of now are Protagonist Therapeutics (PTGX), AxoGen (AXGN), Western Digital (WDC) and Phunware (PHUN).
Earnings Estimates Moving Higher for Protagonist Therapeutics (PTGX): Time to Buy?
Protagonist Therapeutics (PTGX) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Are You Looking for a Top Momentum Pick? Why Protagonist Therapeutics (PTGX) is a Great Choice
Does Protagonist Therapeutics (PTGX) have what it takes to be a top stock pick for momentum investors? Let's find out.
Protagonist Therapeutics (PTGX) Upgraded to Buy: What Does It Mean for the Stock?
Protagonist Therapeutics (PTGX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Source: https://incomestatements.info
Category: Stock Reports